Table 1. Area under the curve (AUC) and the corresponding standard error (SE) for each study evaluating the ablity of procalcitonin (PCT) as a biomarker, and the overall estimate using random effects model.

Study	Cut-off (ng/mL)	Time points	N	ROC AUC	SE	95%CI	Tp	Fp	Fn	Tn
Sachse, 1999 (	N/A	N/A	19	N/A	N/A	N/A	N/A	N/A	N/A	N/A
von Heimburg, 1998	3	27	27	N/A	N/A	N/A	2	0	16	9
Neely, 2004	5	62	20	N/A	N/A	N/A	11	12	15	24
Abdel-Hafez 2007	N/A	N/A	42	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Bargues, 2007	0.534	359	25	0.66	0.04	0.59–0.72	39	29	53	237
Lavrentieva, 2007	1.5	934	43	0.98	0.03	0.91–1.04	93	72	21	748
Barati, 2008	0.5	60	60	0.97	0.02	0.93–1.01	30	3	0	27
Bognar, 2010	2	196	28	0.77	0.03	0.70–0.83	73	32	11	78
Lavrentieva, 2012	1.5	139	145	0.97	0.01	0.94–0.99	64	5	9	67
Kim, 2012	2	175	175	0.84	0.03	0.79–0.90	72	15	21	67
Cakir Madenci, 2013	0.759	611	37	0.85	0.02	0.81–0.88	181	79	59	292
Seoane, 2014	1.7	34	34	0.55	0.11	0.33–0.77	4	0	12	18
Paratz, 2014	1.4	345	54	0.62	0.04	0.54–0.70	38	190	10	106
Mokline, 2015	0.69	121	121	0.93	0.03	0.87–0.98	39	12	5	65
Total (AUC random effects)				0.83	0.04	0.76–0.90
Q				182.0
p-value				<0.001
I2				95%

N—total number of individuals; ROC AUC—receiver operating characteristic area under the curve; 95%CI—95% confidence interval; Fn—false negative; Fp—false positive; N/A–not available; Tn—true negative; Tp—true positive.